Don’t throw out the baby with the bath water!

Körner SK, Dreyer T, Carus A, et al. DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer. Scan J Urol. 2024;59:39–46.

https://doi.org/10.2340/sju.v59.24024 DOI: https://doi.org/10.2340/sju.v59.24024

EAU Guidelines 2024, chapter 7: Muscle-invasive and Metastatic Bladder Cancer. https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/chapter/disease-management

Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45(3):297–303.

https://doi.org/10.1016/j.eururo.2003.09.019 DOI: https://doi.org/10.1016/j.eururo.2003.09.019

Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859.

https://doi.org/10.1056/NEJMoa022148 DOI: https://doi.org/10.1056/NEJMoa022148

Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927–1934.

https://doi.org/10.1016/S0140-6736(03)13580-5 DOI: https://doi.org/10.1016/S0140-6736(03)13580-5

Yin M, Yoshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist. 2016;21:708.

https://doi.org/10.1634/theoncologist.2015-0440 DOI: https://doi.org/10.1634/theoncologist.2015-0440

Holmsten K, Omland L, Als A, et al. Implications for efficacy and safety of total sose and dose-intensity of neoadjuvant gemcitabine-cisplatin in muscle-invasive bladder cancer: three-week versus four-week regimen. Bladder Cancer. 2021;8(1):71–80.

https://doi.org/10.3233/BLC-211556 DOI: https://doi.org/10.3233/BLC-211556

Aydin AM, Cheriyan SK, Reich R, et al. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer Urol Oncol. 2022;40(10):453.e19–453.e26.

https://doi.org/10.1016/j.urolonc.2022.05.023 DOI: https://doi.org/10.1016/j.urolonc.2022.05.023

Chakraborty A, Hasler JS, Handorf EA, et al. Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles. ASCO abstract 2023, ©2023 by American Society of Clinical Oncology. ASCO congress, June 2-6, 2023, Chicago, Illinois, USA. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.4586

D’Andrea D, Black PC, Zargar H, et al. Identifying the optimal number of neoadjuvant chemotherapy cycles in patients with muscle invasive bladder vancer. J Urol. 2022;207(1):70–76. DOI: https://doi.org/10.1097/JU.0000000000002190

Patel HD, Patel SH, Blanco-Martinez E, et al. Four versus 3 cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: implications for pathological response and survival. J Urol 2022;207(1):77–85.

https://doi.org/10.1097/JU.0000000000002189 DOI: https://doi.org/10.1097/JU.0000000000002189

Eriksson V, Holmlund J, Wiberg E, et al. Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer – a Swedish retrospective multicentre study of a clinical database. Transl Androl Urol. 2022;11(8):1105–1115.

https://doi.org/10.21037/tau-22-78 DOI: https://doi.org/10.21037/tau-22-78

DaBlaCa. Nationale kliniske retningslinier for behandling af blæretumorer i Danmark (in Danish): Danish Urological Society. 2016. Available from: http://skejby.net/Webudgaven/Pdf/DaBlaCa_april_2016.pdf

Nielsen N, Wrist Lam G, Fabrin K, Holt P, Thind PO, Jensen JB. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy. Scand J Urol. 2019;53(4):213–216.

https://doi.org/10.1080/21681805.2019.1624608 DOI: https://doi.org/10.1080/21681805.2019.1624608